614730-96-0

Basic information

• Product Name: TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE;4-Cyano-4-(hydroxymethyl)-1-piperidinecarboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 4-cyano-4-(hydroxyMethyl)-, 1,1-diMethylethyl ester;1-BOC-4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE;2-Methyl-2-propanyl 4-cyano-4-(hydroxyMethyl)-1-piperidinecarboxylate;tert-butyl 4-cyano-4-(hydroxyMethyl);tert-Butyl 4-cyano-4-(hydroxymethyl)piperidin-1-carboxylate
• CAS NO: 614730-96-0
• Molecular Formula: C₁₂H₂₀N₂O₃
• Molecular Weight: 240.301
• Mol File: 614730-96-0.mol

Chemical Properties

• Boiling Point: 382.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.14
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.94±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE(614730-96-0)
• EPA Substance Registry System: TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE(614730-96-0)

Safety Data

• Hazardous Substances Data: 614730-96-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new medicinal compounds. Its unique structure allows for the creation of diverse drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE serves as an essential intermediate in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these products aids in enhancing crop protection and improving agricultural yields.
Used in Chemical Research:
TERT-BUTYL 4-CYANO-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE is also utilized in chemical research for the exploration of new chemical reactions and the synthesis of novel compounds. Its structural features make it a valuable tool for studying the properties and potential applications of related piperidine derivatives.

InChI:InChI=1S/C12H20N2O3/c1-11(2,3)17-10(16)14-6-4-12(8-13,9-15)5-7-14/h15H,4-7,9H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 4395-98-6 4-cyanopiperidine 
• 1016258-66-4 1-(tert-butyl) 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 162686-53-5 C₁₄H₁₈N₂O 
• 50-00-0 formaldehyd 

Downstream Products

• 929302-00-1 tert-butyl 4-cyano-4-({[(4-methylphenyl)sulfonyl]oxy}methyl)piperidine-1-carboxylate 
• 1416984-93-4 N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichlorobenzamide 
• 1416984-76-3 tert-butyl 4-(aminomethyl)-4-(hydroxymethyl)piperidine-1-carboxylate 
• 1416984-84-3 tert-butyl 4-((3,5-dichlorobenzamido)methyl)-4-(hydroxymethyl)piperidine-1-carboxylate 
• 1416984-94-5 3,5-dichloro-N-((4-(hydroxymethyl)piperidin-4-yl)methyl)benzamide hydrochloride 
• 1207178-51-5 C₁₂H₂₁N₃O₂ 

Relevant articles and documents

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula I ( I ), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

Protein Modification at Tyrosine with Iminoxyl Radicals

Post-translational modifications (PTMs) of proteins are a biological mechanism for reversibly controlling protein function. Synthetic protein modifications (SPMs) at specific canonical amino acids can mimic PTMs. However, reversible SPMs at hydrophobic amino acid residues in proteins are especially limited. Here, we report a tyrosine (Tyr)-selective SPM utilizing persistent iminoxyl radicals, which are readily generated from sterically hindered oximes via single-electron oxidation. The reactivity of iminoxyl radicals with Tyr was dependent on the steric and electronic demands of oximes; isopropyl methyl piperidinium oxime 1f formed stable adducts, whereas the reaction of tert-butyl methyl piperidinium oxime 1o was reversible. The difference in reversibility between 1f and 1o, differentiated only by one methyl group, is due to the stability of iminoxyl radicals, which is partly dictated by the bond dissociation energy of oxime O-H groups. The Tyr-selective modifications with 1f and 1o proceeded under physiologically relevant, mild conditions. Specifically, the stable Tyr-modification with 1f introduced functional small molecules, including an azobenzene photoswitch, to proteins. Moreover, masking critical Tyr residues by SPM with 1o, and subsequent deconjugation triggered by the treatment with a thiol, enabled on-demand control of protein functions. We applied this reversible Tyr modification with 1o to alter an enzymatic activity and the binding affinity of a monoclonal antibody with an antigen upon modification/deconjugation. The on-demand ON/OFF switch of protein functions through Tyr-selective and reversible covalent-bond formation will provide unique opportunities in biological research and therapeutics.

Synthesis of 1,4- and 1,4,4-substituted piperidines for the inhibition of neuronal T-type Ca2+ channels and mitigation of neuropathic pain in mice

A dysregulation in function of neuronal low-voltage-activated T-channel causes neuropathic pain. A group of ten 1,4-disubstituted and 1,4,4-trisubstituted piperidines were synthesized through short sequences of reactions from 4-cyanopiperidine, which may potentially produce a library of analogs. Inhibitions of T-channel in rat dorsal root ganglion neurons and/or Cav3.2 channel in human embryonic kidney-293 cells were screened, and subsequent analgesic effects and inhibition of seizure in pentylenetetrazole-induced seizure mouse model were examined. The two most promising piperidine molecules showed analgesic effects in rat model using a spared nerve injury protocol. One displayed a long withdrawal latency in response to thermal stimulation, and an 80% increase in mechanical threshold assessment studies.

QUINAZOLINE COMPOUND FOR EGFR INHIBITION

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.

PYRIDYL PIPERIDINES

The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4- piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor

The T-type calcium channel inhibitor Mibefradil was reported to protect the heart from atrial remodeling, a key process involved in the development of atrial fibrillation and arrhythmias. Mibefradil is not a selective T-type calcium channel inhibitor and also affects the function of different ion channels. Our aim was to develop a selective T-type calcium channel inhibitor to validate the importance of T-type-related pharmacology in atrial fibrillation. Structural optimisation of a previously disclosed hit series focussed on minimising exposure to the central nervous system and improving pharmacokinetic properties, while maintain adequate potency and selectivity. This resulted in the design of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4- piperidyl]methyl]-3,5-dichloro-benzamide, a novel, selective, peripherally restricted chemical probe to verify the role of T-type calcium channel inhibition on atrial fibrillation protection.